In the second installment of our AI for health plans video series, Avalere is joined by experts Mia Bolton and Teddy Gedamu from Tenasol to discuss how plans are operationalizing enterprise clinical data.
Join Avalere to learn about the new Medicare Prescription Payment Plan and what it means for Part D enrollees in 2025.
In the first installment of our AI for health plans video series, Avalere is joined by experts Mia Bolton and Teddy Gedamu from Tenasol to discuss the regulatory and market dynamics around clinical data and what this means for health plans.
Join Avalere experts to learn about the changes to Part D formularies for 2025 and implications for patient access.
Avalere experts will examine changes in Part D plan options and premiums for 2025 and will explore how these shifts may affect patient costs and choice.
Join our webinar to learn how Part D redesign and drug price negotiation will shape the Plan Year 2026 market, and what this means for manufacturers and plans.
Ahead of the American Society of Nephrology Kidney Week, Avalere experts dive into the key regulatory and legislative developments related to kidney disease that expect to see action in the remaining weeks of 2024.
A new Avalere analysis reaffirms 2021 findings that first identified variability in Medicaid physician office and pharmacy vaccine reimbursement policies.
Join Avalere for an overview of how the Medicare Part D benefit will be changing in 2025 under the Inflation Reduction Act.
The number of PDP and MA-PD options are declining by 26% and 7%, respectively, in 2025.
Join us for a webinar exploring the RNA-Based Therapy landscape.
Avalere finds that between 0.1% and 0.2% of Medicare FFS beneficiaries would experience lower OOP costs for the Part B drugs subject to Q3 2024 inflation rebates.
With the release of the IPAY 2026 MFPs, health plans should analyze the impact to formularies and identify opportunities for contracting changes.
In this installment of our women's health video series, Sarah Kellogg Neff, CEO of the Lactation Network, joins Avalere to explore the value of access to lactation services.
Updates in the Initial IPAY 2027 ICR highlight the increasing needs for specific evidence planning and generation for industry to prepare for negotiation.
With key health policy differences between presidential candidates, the 2024 elections are an inflection point for the future of US healthcare.
Experts from Avalere, part of Avalere Health, and guests discuss the 2024 elections, exploring the candidates’ health policy approaches and implications for stakeholders.
In this installment of our women's health video series, Avalere is joined by Jessica Bell van der Wal, co-Founder and CEO of Frame Fertility, for a discussion of the myths, challenges, and future surrounding family-forming care.
On June 5, The Evidence Base published an article entitled, “Navigating uncertainty: redefining healthcare value in an evolving healthcare landscape,” covering key topics from Avalere’s ISPOR theater session.
In the first installment of our women's health video series, Avalere sits down with Dr. Madhavi Vemireddy of caregiving platform Cleo to discuss the impact caregiving can have on one’s mental health.
